Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia

Open access
Xu, Zi-Jun, Gu, Yu, Wang, Cui-Zhu, Jin, Ye, Wen, Xiang-Mei, Ma, Ji-Chun, Tang, Li-Juan, Mao, Zhen-Wei, Qian, Jun, Lin, Jiang·2020·OncoImmunology

Abstract

Hematological malignancies possess a distinctive immunologic microenvironment compared with solid tumors. Here, using an established computational algorithm (CIBERSORT), we systematically analyzed the overall distribution of 22 tumor-infiltrating leukocyte (TIL) populations in more than 2000 bone marrow (BM) samples from 5 major hematological malignancies and healthy controls. Focusing on significantly altered TILs in acute myeloid leukemia (AML), we found that patients with AML exhibited increased frequencies of M2 macrophages, compared to either healthy controls or the other four malignancies. High infiltration of M2 macrophages was associated with poor outcome in AML. Further analysis revealed that CD206, a M2 marker gene, could faithfully reflect variation in M2 fractions and was more highly expressed in AML than normal controls. High CD206 expression predicted inferior overall survival (OS) and event-free survival (EFS) in two independent AML cohorts. Among 175 patients with intermediate-risk cytogenetics, the survival still differed greatly between low and high CD206 expressers (OS; P < .0001; 3-year rates, 56% v 32%; EFS; P < .001; 3-year rates, 47% v 25%). When analyzed in a meta-analysis, CD206 as a continuous variable showed superior predictive performance than classical prognosticators in AML (BAALC, ERG, EVI1, MN1, and WT1). In summary, M2 macrophages are preferentially enriched in AML. The M2 marker CD206 may serve as a new prognostic marker in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2019.1683347

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 208

Metadata

Authors
Xu, Z.-J., Gu, Y., Wang, C.-Z., Jin, Y., Wen, X.-M., Ma, J.-C., Tang, L.-J., Mao, Z.-W., Qian, J., & Lin, J.
Venue
OncoImmunology
Published
2019-11-03
Volume
9
Issue
1
Pages
1683347-1683347
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2984876778
Cited by
208
References
6
FWCI
9.06
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia. https://app.cochat.ai/papers/10.1080/2162402x.2019.1683347
The paper
Xu, Z.-J., Gu, Y., Wang, C.-Z., Jin, Y., Wen, X.-M., Ma, J.-C., Tang, L.-J., Mao, Z.-W., Qian, J., & Lin, J. (2020). The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia. OncoImmunology. https://doi.org/10.1080/2162402x.2019.1683347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.